Comparative Pharmacology
Head-to-head clinical analysis: KADCYLA versus LARTRUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KADCYLA versus LARTRUVO.
KADCYLA vs LARTRUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
Olaratumab is a recombinant human IgG1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Terminal elimination half-life is approximately 11 days (range 4–20 days), supporting a 3-week dosing interval when combined with doxorubicin.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Olaratumab is cleared primarily via proteolytic catabolism; no specific renal or biliary excretion studies have been conducted. In patients, only trace amounts are excreted in urine (<1% of dose).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent